Introduction {#s1}
============

Heterogeneity is a major feature of pediatric septic shock, including widely variable mortality risk [@pone.0086242-Hanna1]. In the absence of tools to accurately assess mortality risk, clinicians have little objective information to benchmark septic shock outcomes, adjust for risk in analyses of clinical data, risk stratify patients for interventional clinical trials, and guide decisions on which patients need the most aggressive treatment, and which do not. We recently reported the derivation and validation of the pediatric sepsis biomarker risk model (PERSEVERE; PEdiatRic SEpsis biomarkEr Risk modEl) [@pone.0086242-Wong1]. PERSEVERE was derived using a Classification and Regression Tree (CART) approach to predict 28-day mortality. The derivation selected five biomarkers and age, from among twelve biomarkers (serum proteins) and clinical variables potentially associated with outcome. Importantly, PERSEVERE was derived using data measured during the first 24 hours of presentation to the pediatric intensive care unit (PICU) with septic shock, which is an optimal time for risk stratification. In addition, participants were drawn from multiple centers in the United States [@pone.0086242-Kaplan1]--[@pone.0086242-Standage1].

Updating risk models using larger learning data sets can enhance generalizability and reliability. After the initial derivation and validation of PERSEVERE, we therefore combined the derivation and validation cohorts (n = 355) and updated PERSEVERE [@pone.0086242-Wong1]. The purpose of the current study is to formally test the prognostic accuracy of the updated version of PERSEVERE using an independent test cohort, which is a critical next step after updating the model. The study is reported following the STARD (STAndards for the Reporting of Diagnostic accuracy studies) initiative [@pone.0086242-Bossuyt1].

Methods {#s2}
=======

Ethics statement and test cohort study subjects {#s2a}
-----------------------------------------------

The test cohort subjects were pooled from four sources, all of which used the same definition for septic shock [@pone.0086242-Goldstein1]. The Institutional Review Boards (IRB) of each participating institution approved secondary use of biological specimens and clinical data: Cincinnati Children\'s Hospital Medical Center, The Children\'s Hospital of Philadelphia, Yale University School of Medicine, Ann & Robert H. Lurie Children\'s Hospital of Chicago, Children\'s Hospital and Research Center Oakland, Penn State Hershey Children\'s Hospital, Children\'s Mercy Hospital, Children\'s Hospital of Orange County, Akron Children\'s Hospital, Nationwide Children\'s Hospital, Children\'s National Medical Center, Morgan Stanley Children\'s Hospital, Columbia University Medical Center, Miami Children\'s Hospital, Texas Children\'s Hospital, CS Mott Children\'s Hospital at the University of Michigan, St. Christopher\'s Hospital for Children, and Children\'s Hospital of Wisconsin. Written consent was obtained from the parents or legal guardians of all subjects enrolled. None of the test cohort subjects were included in the original derivation or validation of PERSEVERE.

Eighty-seven subjects were included from an ongoing genomics study in pediatric septic shock being conducted at 17 participating institutions [@pone.0086242-Cvijanovich1]--[@pone.0086242-Wong8]. Briefly, children ≤10 years of age admitted to the PICU and meeting pediatric-specific criteria for septic shock were eligible for enrollment. After written informed consent from parents or legal guardians, serum samples were obtained within 24 hours of initial presentation to the PICU with septic shock. The current analysis included subjects enrolled between September 2011 and May 2013.

Sixty subjects were included from among those enrolled in an ongoing, quality improvement program at Cincinnati Children\'s Hospital Medical Center (CCHMC), Cincinnati, Ohio. The program uses PERSEVERE to benchmark septic shock outcomes for all patients admitted to the CCHMC PICU with septic shock. Enrollment procedures are identical to those described above, except that there is no age restriction and the CCHMC IRB has granted permission for waiver of informed consent. Serum samples are collected from residual blood samples in the clinical laboratory. Subjects from this source were enrolled between May 2012 and May 2013.

Nineteen subjects (age range: 8 days to 18 years) were participants in a prospective, observational study at Ann & Robert H. Lurie Children\'s Hospital of Chicago, Chicago, Illinois, evaluating nitric oxide metabolism and mitochondrial function in children with septic shock [@pone.0086242-Weiss1]. Of the 30 subjects with septic shock enrolled in that study, 19 had serum samples available for analysis. The current analysis included subjects enrolled between May 2009 and June 2010.

Sixteen subjects (age range: 2 to 20 years old) were participants in a prospective, observational study at Yale-New Haven Children\'s Hospital, New Haven, Connecticut, evaluating angiopoietin levels in children with septic shock [@pone.0086242-Giuliano1]. Of the 17 subjects with septic shock enrolled in that study, 16 had serum samples available for analysis. The current analysis included subjects enrolled between September 2009 and December 2011.

Study procedures {#s2b}
----------------

For all studies, annotated clinical and laboratory data were collected daily while the participant was in the PICU. Illness severity was calculated prospectively using the Pediatric Risk of Mortality (PRISM) score [@pone.0086242-Pollack1]. The number of organ failures during the initial 7 days of PICU admission was recorded using pediatric-specific criteria [@pone.0086242-Goldstein1]. PICU free days were calculated by subtracting the actual PICU length of stay from a theoretical maximum PICU length of stay of 28 days. Patients with a PICU length of stay greater than 28 days and patients who died during the 28-day study period were classified as having zero PICU free days. All-cause mortality was tracked up to 28 days after meeting criteria for septic shock.

Biomarkers {#s2c}
----------

PERSEVERE includes C-C chemokine ligand 3 (CCL3), interleukin 8 (IL8), heat shock protein 70 kDa 1B (HSPA1B), granzyme B (GZMB), and matrix metallopeptidase 8 (MMP8). Serum concentrations of these biomarkers were measured using a multi-plex magnetic bead platform (MILLIPLEX™ MAP) designed for this project by the EMD Millipore Corporation (Billerica, MA). Biomarker concentrations were measured in a Luminex® 100/200 System (Luminex Corporation, Austin, TX), according the manufacturers\' specifications. Assay performance data were previously published [@pone.0086242-Wong1].

Statistical Analysis {#s2d}
--------------------

Initially, data are described using medians, interquartile ranges, frequencies, and percentages. Comparisons between groups used the Mann-Whitney U-test, Chi-square, or Fisher\'s Exact tests as appropriate. Descriptive statistics and comparisons used SigmaStat Software (Systat Software, Inc., San Jose, CA).

CART analysis was used to derive, validate, and update PERSEVERE (Salford Predictive Modeler v6.6, Salford Systems, San Diego, CA) [@pone.0086242-Wong1], [@pone.0086242-Che1], [@pone.0086242-Muller1]. Performance of the resulting decision tree in this new test cohort is reported using diagnostic test statistics with 95% confidence intervals computed using the score method as implemented by the VassarStats Website for Statistical Computation [@pone.0086242-Lowry1]. The net reclassification improvement (NRI) was used to estimate the incremental predictive ability of the biomarker-based model compared to using PRISM scores alone [@pone.0086242-Steyerberg1]. The NRI was computed using the R-package Hmisc.

Results {#s3}
=======

Characteristics of the derivation and validation cohorts {#s3a}
--------------------------------------------------------

[Table 1](#pone-0086242-t001){ref-type="table"} describes the new test cohort (n = 182), and compares this to the previously published derivation cohort (n = 355). The test cohort had a higher median age and a greater proportion of subjects with no race reported. No other differences were observed. Within the test cohort, the only difference between survivors and non-survivors was the median PRISM score.

10.1371/journal.pone.0086242.t001

###### Demographics and clinical characteristics of the derivation and test cohorts.

![](pone.0086242.t001){#pone-0086242-t001-1}

                                                                    Derivation Cohort   Test Cohort                                                                           
  ---------------------------------------------------------------- ------------------- ------------- ------------ --------------------------------------------- ------------- ------------------------------------------
  N                                                                        355              314           41                           182                           158                          24
  Mortality (%)                                                           11.5              --            --                          13.2                           --                           --
  Median days to death                                                     --               --            3                            --                            --                           4
  (IQR)                                                                                                (2--12)                                                                                  (2--6)
  Mean days to death ±SD                                                   --               --         7.5±8.5                         --                            --                        4.6±4.2
  Median age years                                                         2.4              2.5          1.9                           5.5                           5.6                         5.0
  (IQR)                                                                (0.9--6.1)       (1.0--6.3)    (0.5--5.6)   (1.6--13.0)[2](#nt102){ref-type="table-fn"}   (1.7--13.1)                  (0.6--9.0)
  Median PRISM score                                                       13               12            26                           11                            11                           19
  (IQR)[1](#nt101){ref-type="table-fn"}                                  (7--20)          (7--19)      (17--36)                      (9--18)                       (8--15)     (13--25)[3](#nt103){ref-type="table-fn"}
  \# of males (%)                                                       207 (58)         183 (58)      24 (59)                       94 (52)                       81 (51)                     13 (54)
  \# of females (%)                                                     148 (42)         131 (42)      17 (41)                       88 (48)                       77 (49)                     11 (46)
  \# for race (%)                                                                                                                                                             
  *Caucasian*                                                           266 (75)         237 (75)      29 (71)                      129 (71)                      112 (71)                     17 (71)
  *African American*                                                     54 (15)          48 (15)       6 (15)                       20 (11)                       18 (11)                      2 (8)
  *Other*                                                                18 (5)           15 (5)        3 (7)                         3 (2)                         1 (1)                       2 (8)
  *Unreported*                                                           17 (5)           14 (4)        3 (7)        30 (16)[2](#nt102){ref-type="table-fn"}       27 (17)                      3 (13)
  \# with gram (+) bacteria (%)                                          97 (27)          85 (27)      12 (29)                       54 (30)                       46 (29)                      8 (33)
  \# with gram (−) bacteria (%)                                          82 (23)          73 (23)       9 (22)                       39 (21)                       31 (20)                      8 (33)
  \# with viral infection (%)                                            26 (7)           22 (7)        4 (10)                        9 (5)                         5 (3)                       4 (17)
  \# with fungal infection (%)                                            9 (3)            8 (3)        1 (2)                         7 (4)                         7 (4)                       0 (0)
  \# with no organism isolated (%)                                      144 (41)         129 (41)      15 (37)                       80 (44)                       75 (47)                      5 (21)
  \# with any co-morbidity (%)                                          143 (40)         127 (40)      16 (39)                       69 (38)                       60 (38)                      9 (38)
  \# with malignancy (%)                                                 34 (10)          31 (10)       3 (7)                        16 (9)                        15 (9)                       1 (4)
  \# with immune suppression (%)[4](#nt104){ref-type="table-fn"}         29 (8)           26 (8)        3 (7)                        17 (9)                        13 (8)                       4 (17)

Nineteen subjects (18 survivors and 1 non-survivor) in the test cohort did not have available PRISM scores.

p\<0.05 vs. test cohort.

p\<0.05 vs. respective survivors.

Refers to patients with immune suppression not related to cancer (for example, those receiving immune suppressive medication for solid organ or bone marrow transplantation, or those with a primary immune deficiency).

Testing the model {#s3b}
-----------------

The test cohort subjects were classified based on the decision rules of the updated model, without any modifications. [Figure 1](#pone-0086242-g001){ref-type="fig"} shows the classification of the test cohort subjects according to the updated decision tree, which includes three low risk terminal nodes (TN2, TN4, and TN7; mortality probability 0.000 to 0.025), three intermediate risk terminal nodes (TN1, TN3, and TN5; mortality probability 0.182 to 0.267), and two high-risk terminal nodes (TN6 and TN8; mortality probability 0.472 to 0.625). There were 123 test cohort subjects classified as low risk and 59 subjects classified as either intermediate or high risk. Among the low risk subjects, four (3.3%) had died by 28 days. Among the intermediate and high-risk subjects 20 (33.9%) had died by 28 days. [Table 2](#pone-0086242-t002){ref-type="table"} shows the diagnostic test characteristics of the decision tree in the test cohort.

![Classification of the test cohort subjects according to the updated version of PERSEVERE.\
The classification tree consists of 6 biomarker-based decision rules, 1 age-based decision rule, 14 daughter nodes, and 8 terminal nodes. The classification tree includes C-C chemokine ligand 3 (CCL3), heat shock protein 70 kDa 1B (HSPA1B), interleukin-8 (IL8), granzyme B (GZMB), and matrix metalloproteinase-8 (MMP8). Each node provides the total number of subjects in the node, the biomarker serum concentration- or age-based decision rule, and the number of survivors and non-survivors with the respective rates. For consistency, the serum concentrations of all stratification biomarkers are provided in pg/ml. The terminal nodes are numbered TN1 through TN8, and each terminal node provides the actual mortality and survival rates for the respective test cohort subjects, as well as the respective mortality probability of the updated decision tree, in parentheses. Terminal nodes 2, 4, and 7 are low risk terminal nodes (mortality probability 0.000 to 0.025), terminal nodes 1, 3, and 5 are intermediate risk terminal nodes (mortality probability 0.182 to 0.267), and terminal nodes 6 and 8 are high-risk terminal nodes (mortality probability 0.472 to 0.625). To calculate the diagnostic test characteristics, all subjects in the low risk terminal nodes (n = 123) were classified as predicted survivors, whereas all subjects in the intermediate and high risk terminal nodes (n = 59) were classified as predicted non-survivors.](pone.0086242.g001){#pone-0086242-g001}

10.1371/journal.pone.0086242.t002

###### Diagnostic test characteristics of the decision tree.

![](pone.0086242.t002){#pone-0086242-t002-2}

  ----------------------------- ----------------------
  Number of Subjects                     182
  Overall Predicted Mortality      9.3% (7.2--11.3)
  Number of True Positives                20
  Number of True Negatives               119
  Number of False Positives               39
  Number of False Negatives               4
  Sensitivity                        83% (62--95)
  Specificity                        75% (68--82)
  Positive Predictive Value          34% (22--47)
  Negative Predictive Value          97% (91--99)
  +Likelihood Ratio                   (2.4--4.7)
  −Likelihood Ratio                 0.2 (0.1--0.5)
  Area Under the Curve           0.811 (0.704--0.917)
  ----------------------------- ----------------------

When adding the information in PERSEVERE to the information in PRISM, the NRI was 0.906 (95% CI: 0.465--1.350; p\<0.001). The NRI is a measure of how much the accuracy of predicted outcomes is improved when adding information [@pone.0086242-Steyerberg1]. The NRI ranges between −2 and +2. A score of −2 indicates that all true positives are reclassified as false negatives and all true negatives are reclassified as false positives, and no false classifications are reclassified as true classifications. Conversely, when the score is 2, adding the information correctly reclassifies every case. Our results demonstrate that the PERSEVERE provides significant additional classification value beyond the information included in PRISM.

Secondary considerations {#s3c}
------------------------

In our prior study, we noted that subjects classified as false positives (i.e. those predicted to die, but who actually survived) had greater illness severity than the true negative subjects (i.e. those predicted to survive, who did survive), as measured by PICU length of stay and organ failure burden [@pone.0086242-Wong1]. We conducted a similar secondary analysis for the current test cohort. [Table 3](#pone-0086242-t003){ref-type="table"} shows that the false positive subjects in the test cohort had greater illness severity than the true negative subjects as measured by PICU length of stay, PICU free days, organ failure burden, and organ failure duration.

10.1371/journal.pone.0086242.t003

###### Clinical course of the true negatives and the false positives.

![](pone.0086242.t003){#pone-0086242-t003-3}

                                                     True Negatives   False Positives   p value
  ------------------------------------------------- ---------------- ----------------- ---------
  Number                                                  119               39         
  Median PICU length of stay, days (IQR)                4 (3--9)         7 (4--13)       0.005
  Median PICU free days (IQR)                         24 (19--25)       21 (15--24)      0.005
  Median maximum number of organ failures (IQR)         1 (1--2)         3 (2--3)       \<0.001
  Number with ≥2 organ failures at PICU day 7 (%)       12 (10)           18 (46)       \<0.001

Discussion {#s4}
==========

Risk models require updating and ongoing prospective evaluation in order to enhance generalizability and acceptance. We have prospectively evaluated the prognostic accuracy of the updated version of PERSEVERE and found that it estimates mortality probability reliably in a heterogeneous test cohort. Among subjects predicted to be at intermediate or high-risk, the overall mortality rate was 33.9%, whereas subjects classified as low risk had an overall mortality rate of 3.3%. This dichotomous interpretation of PERSEVERE partitions a heterogeneous cohort of patients with septic shock into two groups having a ten-fold difference in mortality.

A more comprehensive view of PERSEVERE is to view each terminal node in the decision tree, and to assign individual patients with a mortality risk based on the probability of death in that terminal node. This allows for assigning a range of clinically relevant mortality probabilities and the ability to partition patients into low, intermediate, and high-risk groups. Moreover, the current validation study also demonstrates that PERSEVERE adds significant prognostic value to a physiology-based scoring system.

PERSEVERE generates reliable mortality risk prediction, but is imperfect; 21% of the test cohort subjects were false positives. This is to be expected if therapeutic interventions modify the outcomes of higher risk patients; the false positive subjects likely represent patients for whom therapeutic interventions prevented the predicted death. Support for this assertion is provided by our secondary analysis of the false positive and true negative patients. False positive subjects had a greater burden and duration of organ failure, and a greater PICU length of stay than true negative subjects, suggesting that PERSEVERE accurately identified higher acuity patients. Thus, even when the prediction is a false positive the information is likely clinically relevant.

The current test cohort was significantly older than the derivation cohort with almost one-third of the subjects being greater than 10 years of age. The issue of age is particularly important since the original derivation of PERSEVERE was based exclusively on children less than or equal to 10 years of age, and because developmental age strongly influences the host response during septic shock [@pone.0086242-Wynn1], [@pone.0086242-Wynn2]. As well as expanding the likely generalizability of PERSEVERE to subjects greater than 10 years, the test cohort was pooled from four different sources, each having its own unique potential for selection bias. This suggests that PERSEVERE has the potential for both broad applicability in pediatric septic shock, as well as having the potential to perform reliably in future prospective testing.

PERSEVERE has various potential clinical applications. First, it can be used as a benchmark to objectively evaluate septic shock outcomes. Poor outcomes in patients with a low PERSEVERE-based mortality risk, could suggest clinical underperformance and the need to review the clinical care process, while good outcomes in patients with a high PERSEVERE-based mortality risk could indicate better than expected clinical performance. We note that the actual mortality rate of the test cohort (13.3%) was higher than the overall mortality predicted by PERSEVERE (9.3%; 95% CI 7.2 to 11.3). This discrepancy reflects the four false negative classifications in terminal nodes 2 and 7. Three of these deaths were attributable to a single center, and in the quality peer review of these subjects, it was deemed that the deaths were unlikely to reflect a deficit in the care process. All three subjects had "do not resuscitate" orders in place and died after removal of advanced life support upon determination by the family and health care team that further support was futile. Two subjects had chronic multi-organ dysfunction associated with complications following bone marrow transplantation. The third subject had a lethal, progressive neurodegenerative disease. This illustrates how PERSEVERE can lead to a quality review of the care process, and the challenges inherent to assigning a mortality probability in patients with complex co-morbidities. Future calibrations of PERSEVERE may require the consideration of a co-morbidity variable, including immune function status. We note, however, that many test cohort subjects with significant co-morbidities (n = 45) or immune suppression (n = 12) were correctly classified by PERSEVERE.

Second, PERSEVERE could be used to conduct risk-stratified analyses of clinical data, as demonstrated in a recent study by our group [@pone.0086242-Abulebda1]. We found the influence of positive fluid balance on pediatric septic shock outcomes to depend on risk as predicted by PERSEVERE. A positive fluid balance was associated with poor outcomes in the low mortality risk group, but not in the intermediate or high mortality risk groups. Third, PERSEVERE could be used to stratify patients for interventional clinical trials, and possibly to inform individual patient decision-making. These two latter applications will require the development of a rapid assay platform to generate biomarker data in a timely manner. No assay platform currently exists, but the technology to develop is readily available.

In conclusion, we have taken an important next step in the development of PERSEVERE. We have prospectively tested the prognostic accuracy of the updated version of PERSEVERE and found that it can be used to assign a reliable mortality probability in children with septic shock. This tool has various potential applications in the field of pediatric septic shock.
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